Who are AN2728 ointment, 2%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Clobetasol propionate foam, Topical Fluorometholone, Hydrocortisone Butyrate 0.1% Cream, Clobetasol Ointment, Hydrocortisone butyrate cream, 0.1%, Halobetasol Topical Foam.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/an2728-ointment-2.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

AN2728 ointment, 2% — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AN2728 ointment, 2% (AN2728 ointment, 2%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topical corticosteroid. Area: Dermatology.

phase 2 Topical corticosteroid Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

AN2728 ointment, 2% (AN2728 ointment, 2%) — Pfizer. AN2728 ointment, 2% is a topical corticosteroid that reduces inflammation and itching by suppressing the immune system's response.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
AN2728 ointment, 2% TARGET	AN2728 ointment, 2%	Pfizer	phase 2	Topical corticosteroid
Clobetasol propionate foam	Clobetasol propionate foam	Stiefel, a GSK Company	marketed	Topical corticosteroid (Class I, super-potent)	Glucocorticoid receptor
Topical Fluorometholone	Topical Fluorometholone	Navy Medical Center San Diego	marketed	Topical corticosteroid	Glucocorticoid receptor
Hydrocortisone Butyrate 0.1% Cream	Hydrocortisone Butyrate 0.1% Cream	Peking Union Medical College Hospital	marketed	Topical corticosteroid (Class III/IV potency)	Glucocorticoid receptor
Clobetasol Ointment	Clobetasol Ointment	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	Topical corticosteroid (Class I/super-potent)	Glucocorticoid receptor
Hydrocortisone butyrate cream, 0.1%	Hydrocortisone butyrate cream, 0.1%	Pfizer	marketed	Topical corticosteroid (Class III/IV potency)	Glucocorticoid receptor
Halobetasol Topical Foam	Halobetasol Topical Foam	Mayne Pharma International Pty Ltd	marketed	Topical corticosteroid (Class I, super-potent)	Glucocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AN2728 ointment, 2% — Competitive Intelligence Brief. https://druglandscape.com/ci/an2728-ointment-2. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing